Astrazeneca Plc · LSE:AZN
Astrazeneca — ASCO Annual Meeting analyst and investor meeting 2013
14 slides from Astrazeneca's conference presentation, Jun 1, 2013
Slide 1: ASCO analyst and investor meeting
ASCO analyst and investor meeting 1 June 2013, Chicago, IL
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward- looking statement
Slide 3: Agenda
Agenda 6:30pm Welcome and Introduction 6:35pm Olaparib update Jane Robertson VP Global Product Development 6:45pm Selumetinib update Donna Francher VP Global Product Development 6:55pm Q&A Jane Robertson Donna Francher Susan Galbraith Head of Innovative Medicines Oncology IMED Ed Bradley Head of Med
Slide 4: Olaparib update
Olaparib update Jane Robertson VP Global Product Development 4 4
Slide 5: Study 19: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Study 19: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer 1.0 progression-free survival 0.9 Primary analysis 0.8 (58% maturity; n=154/265) Probability of 0.7 PFS hazard ratio=0.35 0.6 (95% CI 0.25–0.49) 0.5 P<0.00001 0.4 0.3 0.2 Randomized treatment* Placebo (n=129) 0.1 Ol
Slide 6: Methods: BRCAm testing
Methods: BRCAm testing Germline BRCAm (gBRCAm) status was determined retrospectively in an additional 121 patients (218 in total) • The diagnostic assay (Myriad Genetics) used blood samples collected before randomization from consenting patients Since patients without an inherited gBRCAm can develop
Slide 7: PFS by BRCAm status
PFS by BRCAm status BRCAm (n=136) Olaparib Placebo 1.0 Events: total pts (%) 26:74 (35.1) 46:62 (74.2) 0.9 Median PFS, months 11.2 4.3 HR=0.18 Proportion of patients 0.8 95% CI (0.11, 0.31); progression-free 0.7 P<0.00001 0.6 0.5 0.4 0.3 Olaparib BRCAm 0.2 Placebo BRCAm 0.1 0 0 3 6 9 12 15 Time from
Slide 8: OS in BRCAm patients
OS in BRCAm patients BRCAm (n=136) 1.0 Olaparib Placebo Proportion of patients alive 0.9 Deaths: total pts (%) 37:74 (50.0) 34:62 (54.8) 0.8 Median OS, months 34.9 31.9 0.7 HR=0.74 95% CI (0.46, 1.19) 0.6 P=0.208 0.5 0.4 0.3 Randomized treatment 0.2 Olaparib BCRAm 0.1 Placebo BRCAm 0 0 3 6 9 12 15 1
Slide 9: Olaparib development plan 2013
Olaparib development plan 2013 BRCA-mutated ovarian cancer • Platinum-sensitive, relapsed maintenance study with ENGOT • High-risk, first-line ovarian maintenance with GOG BRCA-mutated breast cancer • Metastatic disease with Breast Cancer Alliance • Neoadjuvant (combination with paclitaxel) with Bre
Slide 10: Selumetinib update
Selumetinib update Donna Francher VP Global Product Development 10 10
Slide 11: Monotherapy activity in uveal melanoma (GNAQ)
Monotherapy activity in uveal melanoma (GNAQ) Selumetinib vs. temozolomide in uveal melanoma Scientific / Clinical Context • In contrast to melanomas, uveal melanomas rarely exhibit NRAS / BRAF activation • Commonly possess mutation of GNAQ. Provides an alternate route to MEK-ERK activation1 15.9 we
Slide 12: Accelerating multiple opportunities with selumetinib
Accelerating multiple opportunities with selumetinib Starting pivotal trials 2013 Selumetinib in MEK-driven tumours Effective and well-tolerated as Thyroid GI cancers monotherapy Induces ‘re-differentiation’ in thyroid cancer KRASm NSCLC Active in combination with chemo in multiple tumour type
Slide 13: Selumetinib combination with chemo in NSCLC
Selumetinib combination with chemo in NSCLC Active in combination with Evidence in 2nd-line KRASm NSCLC2 chemotherapy Selumetinib + Placebo + Docetaxel3 Docetaxel3 (N=43) (N=40) High and durable response rate Response 16 (37%) 0 in segment with poor response to docetaxel alone Non- 27 (63%) 40 (10
Slide 14: Q&A
Q&A 14 14
AstraZeneca — ASCO Annual Meeting analyst and investor meeting 2013 on 6ix